Bionano Genomics Stock Today
| BNGO Stock | USD 0.42 0.02 5.00% |
Performance0 of 100
| Odds Of DistressOver 81
|
Bionano Genomics is selling at 0.42 as of the 25th of September 2024; that is 5.00 percent increase since the beginning of the trading day. The stock's open price was 0.4. Bionano Genomics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Bionano Genomics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of June 2024 and ending today, the 25th of September 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 21st of August 2018 | Category Healthcare | Classification Health Care |
Bionano Genomics, Inc. provides genome analysis software solutions. The company was founded in 2003 and is headquartered in San Diego, California. Bionano Genomics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. The company has 86 M outstanding shares of which 3.68 M shares are currently shorted by private and institutional investors with about 1.84 trading days to cover. More on Bionano Genomics
Moving together with Bionano Stock
Moving against Bionano Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Bionano Stock Highlights
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Life Sciences Tools & Services, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBionano Genomics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Bionano Genomics' financial leverage. It provides some insight into what part of Bionano Genomics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bionano Genomics (BNGO) is traded on NASDAQ Exchange in USA. It is located in 9540 Towne Centre Drive, San Diego, CA, United States, 92121 and employs 344 people. Bionano Genomics is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 36.12 M. Bionano Genomics conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 86 M outstanding shares of which 3.68 M shares are currently shorted by private and institutional investors with about 1.84 trading days to cover.
Bionano Genomics currently holds about 187.34 M in cash with (129.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.65, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Bionano Genomics Probability Of Bankruptcy
Ownership AllocationBionano Genomics holds a total of 86 Million outstanding shares. Almost 88.12 percent of Bionano Genomics outstanding shares are held by general public with 0.12 (percent) owned by insiders and only 11.76 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Bionano Ownership Details
Bionano Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Jane Street Group, Llc | 2024-06-30 | 48.5 K | |
| Susquehanna International Group, Llp | 2024-06-30 | 48.4 K | |
| Carret & Company Inc | 2024-06-30 | 45 K | |
| Ipg Investment Advisors, Llc | 2024-06-30 | 40.3 K | |
| Inspire Advisors, Llc | 2024-06-30 | 39.7 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 31.2 K | |
| Dimensional Fund Advisors, Inc. | 2024-06-30 | 31 K | |
| Simplex Trading, Llc | 2024-06-30 | 29.5 K | |
| Justinvest Llc | 2024-06-30 | 29 K | |
| Vanguard Group Inc | 2024-06-30 | 2.1 M | |
| Armistice Capital, Llc | 2024-06-30 | 1.7 M |
Bionano Genomics Historical Income Statement
Bionano Stock Against Markets
Bionano Genomics Corporate Management
| Jonathan JD | General Secretary | Profile | |
| Donna Polizio | Global Access | Profile | |
| Klint Rose | Head Development | Profile | |
| Helene Klein | Chief Officer | Profile | |
| Sheila MBA | Vice Marketing | Profile | |
| Christopher Stewart | Chief Officer | Profile | |
| Jonathan Dixon | Global Legal | Profile |
Additional Information and Resources on Investing in Bionano Stock
When determining whether Bionano Genomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bionano Genomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionano Genomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionano Genomics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bionano Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 9.89 | Revenue Per Share 0.749 | Quarterly Revenue Growth (0.10) | Return On Assets (0.33) | Return On Equity (1.38) |
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.